Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas (TARZAN Trial)

NCT06824701 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT06824701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06824701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas (TARZAN Trial)
Lead sponsor
University of Utah
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 12, 2025
Completion date
January 31, 2033
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory b-cell non-hodgkin lymphoma